Q96RI1 | SWISS-MODEL Repository

Q96RI1 (NR1H4_HUMAN) Homo sapiens (Human)

Bile acid receptor UniProtKB InterPro STRING Interactive Modelling

486 aa; Sequence (Fasta) ; (Isoform 4; Isoform 1; Isoform 2; Isoform 5)

It is possible new templates exist for this target since these models were created.

Available Structures

86 Experimental Structures

Description	PDB ID	Oligo-state	Range	Ligands
FXR with SRC1 and GSK088	3hc6 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	257-486	1×088; 1×SO4;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q0p SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×9LA;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q14 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×9MM;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q0v SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×9LS;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q1d SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×9ND;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q13 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×9MD;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q18 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×9MY;
Assess
Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzi…	3olf SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×OLF;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q0u SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×9LP;
Assess
Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimida…	3omk SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×OMK;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q0o SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×CL; 1×9L7;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q15 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×9MP;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q19 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×9N1;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q1a SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×9N4;
Assess
Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N,2…	3oki SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×OKI;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q16 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×9MS;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q0j SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×9KV;
Assess
Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzi…	3omm SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×OMM;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q0y SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×9LY;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q0z SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×9M1;
Assess
Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzi…	3oof SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×OOF;
Assess
Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzi…	3ook SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×OOK;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q1b SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×9N7;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q1c SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×9NA;
Assess
A unique binding model of FXR LBD with feroline	5ick SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15596;	258-486	1×FEZ;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q0s SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×9LJ;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q0l SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×9KY;
Assess
FXR with SRC1 and GW4064	3dct SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×064;
Assess
FXR with SRC1 and GSK237	3ruu SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	2×SO4; 1×37G;
Assess
FXR with SRC1 and GSK826	3hc5 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×82X; 2×SO4;
Assess
FXR-LBD with HNC180 and SRC1	6a5x SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	5×SO4; 1×9R3;
Assess
FXR with DM175 and NCoA-2 peptide	4qe8 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15596;	258-486	1×31D; 4×EDO;
Assess
FXR bound to isoquinolinecarboxylic acid	3p88 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×P88; 1×SO4;
Assess
FXR with SRC1 and GSK8062	3dcu SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	1×O62;
Assess
A ligand F binding to FXR	5yxd SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15596;	258-486	1×93R;
Assess
FXR with SRC1 and GSK359	3rut SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-486	2×SO4; 1×59G;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q0i SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q9UBK2;	258-485	1×0X0;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q1g SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-485	1×9NM;
Assess
Crystal structure of human FXR in complex with a functional drug ligand	5y1j SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15596;	258-485	1×D5H;
Assess
Crystal structure of human FXR/RXR-LBD heterodimer bound to HNC143 and 9cRA and SRC1	6a5y SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer P19793; Q15788;	258-485	1×9R0; 2×SO4; 1×9CR; 1×PO4;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q0t SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-485	1×9LM;
Assess
CRYSTAL STRUCTURE OF FARNESOID X-ACTIVATED RECEPTOR COMPLEXED WITH COMPOUND-32 AKA (1S,3S)-N-({4-[5…	7trb SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-485	1×IUS;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q1h SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-485	1×9NP;
Assess
Identification of an N-oxide pyridine GW4064 analogue as a potent FXR agonist	3fxv SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-485	1×643;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q0x SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-485	1×643;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q1f SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-485	1×9NJ;
Assess
A novel moderator XD4 for bile acid receptor	5y44 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-485	1×XD4; 1×SO4;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q0n SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-485	1×9L4;
Assess
Crystal structure of human FXR in complex with 2-(4-chlorophenyl)-1-[(1S)-1-cyclohexyl-2-(cyclohexy…	3okh SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-485	2×OKH;
Assess
Crystal structure of FXR in complex with agonist XJ034	6itm SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-485	1×AWL;
Assess
Novel natural FXR modulator with a unique binding mode	5iaw SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15596;	259-486	2×T73;
Assess
FXR ligand binding domain	5yxj SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15596;	258-485	1×93U;
Assess
A structure of FXR/RXR	5z12 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer P19793; Q15596;	259-486	1×33Y; 1×9CR;
Assess
FXR-LBD with HNC143 and SRC1	6a5w SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-485	1×9R0;
Assess
A ligand binding to FXR	5yxb SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15596;	258-485	1×93O;
Assess
Structural basis for a pentacyclic oleanane-type triterpenoid as a ligand of FXR	5wzx SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15596;	258-485	1×7VX; 3×BU3;
Assess
Crystal structure of human FXR/RXR-LBD heterodimer bound to HNC180 and 9cRA and SRC1	6a5z SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer P19793; Q15788;	258-485	1×9R3; 1×9CR;
Assess
Crystal structure of human FXR/RXR-LBD heterodimer bound to GW4064 and 9cRA and SRC1	6a60 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer P19793; Q15788;	258-485	1×064; 1×9CR;
Assess
FXR with SRC1 and GSK2034	3rvf SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	259-486	1×SO4; 1×034;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q0k SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-484
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q1e SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-484	1×9NG;
Assess
Structure of human FXR in complex with MFA-1 and co-activator peptide	3bej SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	259-485	1×YT3; 1×MUF;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q0w SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-484	1×9LV;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q0r SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-484	1×9LG;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q1i SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-484	1×9O1;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q12 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-484	1×9MA;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q17 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15596;	258-484	1×9MV;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q0m SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-484	1×9L1;
Assess
A moderator XD22 binding to bile acid receptor	5y49 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15596;	259-485	1×XD5;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q0q SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-484	1×9LD;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q10 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-483	1×9M4;
Assess
Ligand binding to FARNESOID-X-RECEPTOR	5q11 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	258-483	1×9M7;
Assess
A ligand M binding to FXR	5yxl SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15596;	260-485	1×NIW;
Assess
Structural insight of the molecular mechanism of cilofexor bound to FXR	7vue SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15596;	259-484	1×811;
Assess
Structural basis of tropifexor as a potent and selective agonist for farnesoid X receptor	7d42 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15596;	259-484	1×GWF;
Assess
FXR bound to a quinolinecarboxylic acid	3p89 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer Q15788;	261-485	1×89P; 1×SO4;
Assess
Identification of a novel FXR ligand that regulates metabolism	4wvd SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O75376;	258-468	4×FMT; 1×IVM;
Assess
Structural basis of the farnesoid X receptor/retinoid X receptor heterodimer on inverted repeat DNA	8hbm SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer P19793;	134-206	4×ZN;
Assess
Structural basis for small molecule NDB as a selective antagonist of FXR	4oiv SMTL PDBe PDBe-KB PDBj PDBsum RCSB	homo-2-mer	258-483	2×XX9;
Assess
Crystal Structure of Farnesoid X receptor (FXR) with bound NCoA-2 peptide and CDCA	6hl1 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	monomer	258-486	1×JN3;
Assess
A Chemical, Genetic, and Structural Analysis of the nuclear bile acid receptor FXR	1osh SMTL PDBe PDBe-KB PDBj PDBsum RCSB	monomer	257-485	1×FEX;
Assess
Crystal Structure of Farnesoid X receptor (FXR) with bound NCoA-2 peptide	6hl0 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	monomer	258-485
Assess
Complex Structure of FXR Ligand-binding domain with a tetrahydroazepinoindole compound	3l1b SMTL PDBe PDBe-KB PDBj PDBsum RCSB	monomer	258-485	1×635;
Assess
Discovery of XL335, a Highly Potent, Selective and Orally-Active Agonist of the Farnesoid X Recepto…	3fli SMTL PDBe PDBe-KB PDBj PDBsum RCSB	monomer	258-485	1×33Y;
Assess
Farnesoid X Receptor Agonists_FXR fused with a HD3 peptide	8hd3 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	monomer	258-485	1×XAW;
Assess
isoxazole ligand bound to farnesoid X receptor (FXR)	3gd2 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	monomer	260-486	1×708;
Assess

12 SWISS-MODEL models

Template	Oligo-state	QMEANDisCo	Range	Ligands	Trg-Tpl Seq id (%)
4nqa.1.B	monomer	0.61	129-484	2×ZN;	36.41
Assess
4nqa.2.B	monomer	0.60	129-485	2×ZN;	36.41
Assess
3dzy.1.B	monomer	0.59	134-484	1×ZN;	29.68
Assess
4nqa.1.A	monomer	0.57	132-484	2×ZN;	26.48
Assess
7prv.1.A	monomer	0.56	133-485	2×ZN;	22.36
Assess
7prv.1.B	monomer	0.56	134-485	2×ZN;	22.36
Assess
5uan.1.A	monomer	0.56	135-485	2×ZN;	26.48
Assess
7wnh.4.A	monomer	0.55	137-472	2×ZN;	29.81
Assess
3dzy.1.A	monomer	0.54	134-483	2×ZN;	26.32
Assess
7wnh.2.A	monomer	0.54	136-472	2×ZN;	29.81
Assess
4nqa.1.A	monomer	0.53	136-484	2×ZN;	28.53
Assess
4nqa.2.A	monomer	0.52	136-485	1×ZN;	28.53
Assess

Model ID	Oligo-state	Avg pLDDT	Range	Trg-Mdl Seq Id (%)

Model ID	Oligo-state	Avg Confidence	Range	Trg-Mdl Seq id (%)

42 SWISS-MODEL models built on isoform sequence

Template	Isoform	Oligo-state	QMEANDisCo	Range	Ligands	Trg-Tpl Seq id (%)
Isoform 1	4nqa.1.B	monomer	0.61	119-474	2×ZN;	36.69
Assess
Isoform 1	4nqa.2.B	monomer	0.59	119-475	2×ZN;	36.69
Assess
Isoform 1	3dzy.1.B	monomer	0.59	124-474	1×ZN;	29.68
Assess
Isoform 1	7prv.1.A	monomer	0.57	123-475	2×ZN;	22.59
Assess
Isoform 1	7wnh.4.A	monomer	0.55	127-462	2×ZN;	29.81
Assess
Isoform 1	7prv.1.B	monomer	0.55	124-475	2×ZN;	22.59
Assess
Isoform 1	3dzy.1.A	monomer	0.54	124-473	2×ZN;	26.63
Assess
Isoform 1	7wnh.2.A	monomer	0.54	126-462	2×ZN;	29.81
Assess
Isoform 1	5uan.1.A	monomer	0.53	126-475	2×ZN;	28.53
Assess
Isoform 1	4nqa.1.A	monomer	0.53	126-474	2×ZN;	28.53
Assess
Isoform 1	4nqa.2.A	monomer	0.52	126-475	1×ZN;	28.53
Assess
Isoform 2	4nqa.1.B	monomer	0.64	119-470	2×ZN;	38.42
Assess
Isoform 2	4nqa.2.B	monomer	0.62	119-471	2×ZN;	38.42
Assess
Isoform 2	5uan.1.B	monomer	0.61	126-470	1×ZN;	31.10
Assess
Isoform 2	3dzy.1.B	monomer	0.60	124-470	1×ZN;	29.39
Assess
Isoform 2	4nqa.1.A	monomer	0.58	122-470	2×ZN;	27.73
Assess
Isoform 2	5uan.1.A	monomer	0.57	125-471	2×ZN;	27.73
Assess
Isoform 2	3dzy.1.A	monomer	0.57	124-469	2×ZN;	26.63
Assess
Isoform 2	7prv.1.B	monomer	0.56	124-471	2×ZN;	22.66
Assess
Isoform 2	7prv.1.A	monomer	0.56	123-471	2×ZN;	22.66
Assess
Isoform 2	7wnh.4.A	monomer	0.56	127-458	2×ZN;	29.49
Assess
Isoform 2	7wnh.2.A	monomer	0.55	126-458	2×ZN;	29.49
Assess
Isoform 4	4nqa.1.B	monomer	0.64	129-480	2×ZN;	37.96
Assess
Isoform 4	4nqa.2.B	monomer	0.62	129-481	2×ZN;	37.96
Assess
Isoform 4	3dzy.1.B	monomer	0.59	134-480	1×ZN;	29.39
Assess
Isoform 4	4nqa.1.A	monomer	0.58	132-480	2×ZN;	27.73
Assess
Isoform 4	5uan.1.A	monomer	0.57	135-481	2×ZN;	27.73
Assess
Isoform 4	7wnh.4.A	monomer	0.56	137-468	2×ZN;	29.49
Assess
Isoform 4	3dzy.1.A	monomer	0.56	134-479	2×ZN;	27.33
Assess
Isoform 4	7wnh.2.A	monomer	0.55	136-468	2×ZN;	29.49
Assess
Isoform 4	7kw7.1.F	monomer	0.54	238-482		23.80
Assess
Isoform 5	4nqa.1.B	monomer	0.66	119-423	1×ZN;	33.55
Assess
Isoform 5	4nqa.2.B	monomer	0.64	119-424		33.55
Assess
Isoform 5	4nqa.1.A	monomer	0.60	122-423		22.56
Assess
Isoform 5	5uan.1.A	monomer	0.60	125-424	1×ZN;	22.56
Assess
Isoform 5	3dzy.1.A	monomer	0.60	124-422		22.48
Assess
Isoform 5	7prw.1.B	monomer	0.58	124-424	1×ZN;	20.20
Assess
Isoform 5	7prv.1.A	monomer	0.58	123-424		20.20
Assess
Isoform 5	4nqa.2.A	monomer	0.57	122-424		22.56
Assess
Isoform 5	7wnh.2.A	monomer	0.52	126-411		27.31
Assess
Isoform 5	7wnh.4.A	monomer	0.52	127-411	1×ZN;	27.31
Assess
Isoform 5	4iqr.2.A	monomer	0.51	118-361	1×ZN;	34.38
Assess

Q96RI1 (NR1H4_HUMAN) Homo sapiens (Human)

Bile acid receptor UniProtKBInterProSTRINGInteractive Modelling

Available Structures

86 Experimental Structures

12 SWISS-MODEL models

42 SWISS-MODEL models built on isoform sequence

Alignments

Background

Resolution

Bile acid receptor UniProtKB InterPro STRING Interactive Modelling